Welcome to the Huntington Project
The Huntington Project brings together clinical and basic scientists, individuals and families affected by Huntington’s disease (HD), advocacy groups, and all others in the HD community to find and develop treatments that make a difference in the lives of those affected by HD. By engaging the entire community in the planning and execution of clinical research, the Huntington Project will maximize the efficiency and fruitfulness of the search.
THE HUNTINGTON PROJECT – BASIC PRINCIPLES
• Inclusion of entire HD community
• Broad-based yet coordinated effort
• Respect for all ideas and contributions
• Cooperative spirit
• Commitment to action
Summer 2008 Features:
FDA approves Tetrabenazine!
The U.S. Food and Drug Administration today (August 15, 2008) approved tetrabenazine, the first drug approved for use in the United States to treat Huntington’s disease, a fatal, inherited neurodegenerative disorder for which there is no cure. The action comes about eight months after an advisory panel unanimously voted to advise FDA to make the medication available to treat the disease (read more...).
THE DIMOND TRIAL SHOWS POSITIVE EFFECTS ON COGNITION
Please see the newest article on the Research Spotlight page for more information.
2CARE: COENZYME Q10 IN HUNTINGTON'S DISEASE - THE 2CARE TRIAL IS NOW ENROLLING STUDY PARTICIPANTS
The 2CARE study was launched the week of March 17, 2008. Please see Currently Enrolling for more 2CARE information, as well as other trials that are enrolling participants.
SET-HD
The Huntington Project SET-HD initiative has collected nominations from researchers, scientists, and community members for compounds that may be useful for clinical study in Huntington's disease. Some of these nominations are reviewed in detail in the SET-HD Compound Review section of this web site.
COHORT UPDATE
The first patient was enrolled in COHORT on February 14, 2006. There are over 1,300 participants enrolled, with more participants joining the study weekly. Thank you Huntington’s community and HSG research sites for all of your efforts to propel the COHORT study forward. 42 of the proposed 43 participating research sites are currently up and running and able to enroll participants. The remaining site is processing their paperwork and should be accepting participants soon. We are recruiting individuals with HD and individuals from HD families – please see the COHORT Participating Site list for a site near you.
TETRABENAZINE
December 8, 2007...An FDA advisory committee unanimously recommended approval of tetrabenazine for the treatment of chorea associated with HD. The FDA still must approve the drug, but the committee's unanimous recommendation makes this approval more likely. If approved, tetrabenazine will then become the first drug for HD approved in the
United States.
UPCOMING MEETING LINKS
European HD Network, September 5-8, 2008 (read more...)
World Congress on Huntington's Disease, September 12-15, 2009 (read more...)
Second Annual Huntington Disease Clinical Research Symposium, November 15, 2008 (read more...)